Bristol Myers Squibb - Eight-Year Data for Opdivo Plus Yervo

PRINCETON - Bristol Myers Squibb today announced that Opdivo plus Yervoy continued to demonstrate long-term survival results in the Phase 3 CheckMate -214 trial, reducing the risk of death by 28%...

Related Keywords

United States , Taiwan , South Korea , Japan , China , America , American , Nizar Tannir , Dana Walker , Bristol Myers Squibb , Drug Administration , Division Of Cancer Medicine , Company Opdivo , European Union , University Of Texas , International Metastatic , Md Anderson Cancer Center , Exchange Commission , Department Of Genitourinary Medical Oncology , American Society Of Clinical Oncology , Database Consortium , Ono Pharmaceutical Co , Myers Squibb , Clinical Oncology , Cancers Symposium , Hazard Ratio , Confidence Interval , Genitourinary Medical Oncology , Cancer Medicine , Better Future , Ono Pharmaceutical , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports , News Publishing , Markets ,